Pyelonephritis secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
Line 32: Line 32:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Medicine]]
[[Category:Medicine]]
[[Category:Infectious disease]]
[[Category:Infectious disease]]
Line 37: Line 38:
[[Category:Urology]]
[[Category:Urology]]
[[Category:Up-To-Date]]
[[Category:Up-To-Date]]
[[Category:Primary care]]
[[Category:Emergency medicine]]
[[Category:Emergency medicine]]

Latest revision as of 23:54, 29 July 2020

Urinary Tract Infections Main Page

Pyelonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pyelonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocaridogram

X Ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pyelonephritis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pyelonephritis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pyelonephritis secondary prevention

CDC on Pyelonephritis secondary prevention

Pyelonephritis secondary prevention in the news

Blogs on Pyelonephritis secondary prevention

Directions to Hospitals Treating Pyelonephritis

Risk calculators and risk factors for Pyelonephritis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]

Overview

Pyelonephritis can be prevented secondarily in some cases by giving long term prophylactic antibiotics. Correction of a structural defect that leads to the initial episode of pyelonephritis may also be helpful in eliminating chances of recurrence of pyelonephritis.

Secondary Prevention

  • If no structural or functional abnormality is identified, some studies suggest long-term preventative (prophylactic) treatment with antibiotics, either daily or after sexual intercourse.[1]
  • In children at risk of recurrent UTIs, the evidence is inconclusive as to whether long-term prophylactic antibiotics are of use.[2]
  • Ingestion of cranberry juice has been studied as a prophylactic measure; while studies are heterogeneous, many suggest a benefit.[3]

Antimicrobial Prophylaxis

  • Prophylaxis is required in individuals having two or more episodes of urinary tract infections in 6 months or three or more episodes in 12 months period.[4][5]
  • Prophylactic therapy using antimicrobial agents may be considered as either continuously or postcoital prophylaxis for 6 to 12 months.
  • The following regimens may be used as single doses prior to sexual activity.[6]
  • Prophylactic Therapy:
  • Preferred regimen (1): Fosfomycin tromethamine 3 g PO in a single dose
  • Preferred regimen (2): Nitrofurantoin monohydrate/macrocrystals 100 mg PO in a single dose
  • Preferred regimen (3): Trimethoprim-Sulfamethoxazole 160/800 mg PO double-strength tablet bid in a single dose
  • Preferred regimen (4): Trimethoprim 100 mg PO bid in a single dose
  • Alternative regimen (1): Ciprofloxacin 250 mg PO bid in a single dose
  • Alternative regimen (2): Levofloxacin 250 mg PO qd in a single dose
  • Alternative regimen (3): Norfloxacin 400 mg PO bid in a single dose
  • Alternative regimen (4): Gatifloxacin 200 mg PO qd in a single dose

References

  1. Schooff M, Hill K (2005). "Antibiotics for recurrent urinary tract infections". American family physician. 71 (7): 1301–2. PMID 15832532.
  2. Williams GJ, Wei L, Lee A, Craig JC (2006). "Long-term antibiotics for preventing recurrent urinary tract infection in children". Cochrane database of systematic reviews (Online). 3: CD001534. doi:10.1002/14651858.CD001534.pub2. PMID 16855971.
  3. Raz R, Chazan B, Dan M (2004). "Cranberry juice and urinary tract infection". Clin. Infect. Dis. 38 (10): 1413–9. doi:10.1086/386328. PMID 15156480.
  4. Nicolle LE, Ronald AR (1987). "Recurrent urinary tract infection in adult women: diagnosis and treatment". Infect Dis Clin North Am. 1 (4): 793–806. PMID 3333659.
  5. Ronald AR, Conway B (1988). "An approach to urinary tract infections in ambulatory women". Curr Clin Top Infect Dis. 9: 76–125. PMID 3077293.
  6. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG; et al. (2011). "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases". Clin Infect Dis. 52 (5): e103–20. doi:10.1093/cid/ciq257. PMID 21292654.
  7. Melekos MD, Asbach HW, Gerharz E, Zarakovitis IE, Weingaertner K, Naber KG (1997). "Post-intercourse versus daily ciprofloxacin prophylaxis for recurrent urinary tract infections in premenopausal women". J Urol. 157 (3): 935–9. PMID 9072603.
  8. Brumfitt W, Hamilton-Miller JM (1998). "Efficacy and safety profile of long-term nitrofurantoin in urinary infections: 18 years' experience". J Antimicrob Chemother. 42 (3): 363–71. PMID 9786476.
  9. Rudenko N, Dorofeyev A (2005). "Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study". Arzneimittelforschung. 55 (7): 420–7. doi:10.1055/s-0031-1296881. PMID 16080282.

Template:WH Template:WS